Solasia Pharma K.K.
Tokyo, Japan· Est.
Japanese oncology-focused biopharma company developing and commercializing cancer therapeutics and supportive care products.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese oncology-focused biopharma company developing and commercializing cancer therapeutics and supportive care products.
Oncology
Technology Platform
No proprietary technology platform explicitly described; core expertise lies in oncology drug development, regulatory strategy, and commercialization in Asian markets.
Opportunities
Growth opportunities include geographic expansion of DARVIAS® across Asia and other regions, addressing the high unmet need in Chemotherapy-Induced Peripheral Neuropathy (CIPN) with SP-04, and advancing its new colorectal cancer candidate SP-05.
Risk Factors
Key risks include dependence on a small number of commercial products, clinical development risks for SP-04 and SP-05, and potential competition in supportive care and niche oncology markets.
Operational scalability of a 'small, elite team' may also be a constraint.
Competitive Landscape
Competes in niche oncology (PTCL) and supportive care markets (CINV, oral mucositis, CIPN) against larger pharma and specialty pharma companies. Differentiation is based on regional expertise in Asia, agility in development, and a focus on patient-centric solutions in oncology.